We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
COVID-19 vaccine developers are faced with an ethical quandary — whether to let phase 3 trial participants become “unblinded” and to receive authorized vaccines as they become available, which could hinder the collection of meaningful trial data. Read More
The FDA’s vaccines advisory committee voted almost unanimously on Thursday in favor of Emergency Use Authorization (EUA) for Moderna’s COVID-19 vaccine, with all but one abstaining member supporting clearance, and authorization is widely expected to come today. Read More
“In light of the COVID-19 pandemic, it is even more important to detect other diseases associated with respiratory disease early on, especially for high-risk patient groups,” said François Lacoste, BioMérieux’s executive vice president of R&D. Read More
Moderna has revealed that it was impacted by last week’s cyberattack on the European Medicines Agency (EMA), during which hackers compromised agency computer systems and accessed vaccine regulatory submission documents for Pfizer/BioNTech’s and Moderna’s COVID-19 vaccines. Read More
BD has launched a $1.2 billion program to expand and upgrade its manufacturing capabilities for pre-fillable syringes and advanced drug delivery systems. Read More
“Quantitative antibody testing can help provide greater understanding of a person’s immune response,” said John Hackett, divisional vice president of applied research and technology for Abbott’s diagnostics wing. Read More
“As the flu season overlaps with the second wave of COVID-19, there is an increasing need to be able to quickly distinguish between SARS-CoV-2 and influenza infections,” said Wolfgang Schlumberger, CEO of Euroimmun. Read More
The FDA’s vaccines advisory committee will meet tomorrow to discuss Moderna’s two-dose COVID-19 vaccine and is expected to vote in favor of Emergency Use Authorization (EUA) from the agency. Read More